newsfilter
← Latest News
Business Wire·

2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc. (NASDAQ:TSVT), announced today the completion of an asset purchase agreement ("APA") by Novo Nordisk. Under the